PMID- 16651733
OWN - NLM
STAT- MEDLINE
DCOM- 20060711
LR  - 20190720
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 29
IP  - 5
DP  - 2006 May
TI  - Regulators for blood glucose level affect gene expression of aquaporin 3.
PG  - 991-6
AB  - Aquaporin 3 (AQP3), a membrane protein, is known to permeabilize water and other 
      small molecules such as glycerol and urea and is localized in the bowel, skin, 
      kidney, and erythrocytes. Since glycerol is a nutrient and serves as a source 
      material in glycolytic metabolism, absorption of glycerol in the gastrointestinal 
      tract may be under some control. Therefore we first investigated whether insulin 
      regulating the glycolytic pathway took part in glycerol transport through AQP3 in 
      the gastrointestinal tract and found that insulin significantly suppressed mRNA 
      and protein expressions of AQP3 in Caco-2 cells. The antidiabetic drugs 
      troglitazone and tolbutamide were also observed to suppress significantly AQP3 
      expression, but the biguanides metformin and buformin did not induce such 
      suppression. Epinephrine was found to increase expression of AQP3, although 
      glucagon showed no change of expression. Wortmannin and rapamycin were 
      demonstrated to deactivate suppression of AQP3 expression by insulin and 
      troglitazone, suggesting that the signal transducers, phosphoinositide 3 kinase 
      (PI3K) and the mammalian target of rapamycin (mTOR), are involved in the signal 
      pathway for regulating transcription of AQP3.
FAU - Asai, Mariko
AU  - Asai M
AD  - Department of Pharmaceutics, Gifu Pharmaceutical University, Japan.
FAU - Higuchi, Shouta
AU  - Higuchi S
FAU - Kubota, Masafumi
AU  - Kubota M
FAU - Iguchi, Kazuhiro
AU  - Iguchi K
FAU - Usui, Shigeyuki
AU  - Usui S
FAU - Hirano, Kazuyuki
AU  - Hirano K
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Actins)
RN  - 0 (Androstadienes)
RN  - 0 (Biguanides)
RN  - 0 (Blood Glucose)
RN  - 0 (Chromans)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin Antagonists)
RN  - 0 (RNA, Messenger)
RN  - 0 (Thiazolidinediones)
RN  - 158801-98-0 (Aquaporin 3)
RN  - 9007-92-5 (Glucagon)
RN  - 982XCM1FOI (Tolbutamide)
RN  - I66ZZ0ZN0E (Troglitazone)
RN  - XVA4O219QW (Wortmannin)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Actins/biosynthesis/genetics
MH  - Androstadienes/pharmacology
MH  - Aquaporin 3/*biosynthesis/*genetics
MH  - Biguanides/pharmacology
MH  - Blood Glucose/*metabolism
MH  - Blotting, Western
MH  - Caco-2 Cells
MH  - Chromans/pharmacology
MH  - Epinephrine/pharmacology
MH  - Gene Expression/drug effects
MH  - Glucagon/pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology
MH  - Insulin/pharmacology
MH  - Insulin Antagonists/pharmacology
MH  - RNA, Messenger/biosynthesis/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Signal Transduction/drug effects
MH  - Thiazolidinediones/pharmacology
MH  - Tolbutamide/pharmacology
MH  - Troglitazone
MH  - Wortmannin
EDAT- 2006/05/03 09:00
MHDA- 2006/07/13 09:00
CRDT- 2006/05/03 09:00
PHST- 2006/05/03 09:00 [pubmed]
PHST- 2006/07/13 09:00 [medline]
PHST- 2006/05/03 09:00 [entrez]
AID - JST.JSTAGE/bpb/29.991 [pii]
AID - 10.1248/bpb.29.991 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2006 May;29(5):991-6. doi: 10.1248/bpb.29.991.